Overview

Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Continent Pharmaceutical Co, Ltd.
Treatments:
Pirfenidone